ARS Pharmaceuticals, Inc. — FY 2022 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2022. ARS is a clinical-stage biopharmaceutical company developing neffy, an investigational needle-free intranasal epinephrine product for emergency treatment of Type I allergic reactions, including anaphylaxis. The company had no approved products or product-sale revenue. On November 8, 2022, ARS completed a reverse merger with Silverback Therapeutics; ARS Pharma is the accounting acquirer and provides the historical financial statements.
Financial results and liquidity
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Collaboration revenue | $1.3 million | $5.5 million |
| Research and development expense | $18.4 million | $20.3 million |
| General and administrative expense | $18.5 million | $4.7 million |
| Operating loss | $35.5 million | $19.5 million |
| Net loss | $34.7 million | $20.2 million |
| Net cash used in operating activities | $40.1 million | $17.6 million |
- Revenue and margins: Revenue was collaboration-related, not product sales. The filing provides no meaningful product gross margin; management’s expectation of small-molecule-like margins is conditional on approval and commercialization.
- Cash and liquidity: At year-end, cash and cash equivalents were $210.5 million and short-term investments were $63.9 million, totaling $274.4 million. Current assets were $277.7 million and current liabilities $5.4 million.
- Debt: The company repaid its Silicon Valley Bank note in November 2022; no note payable remained at year-end. Lease liabilities totaled $0.5 million.
- Cash flow and financing: Financing activities provided $190.7 million, primarily from $198.8 million of net merger proceeds, partly offset by $8.7 million of note repayment. Cash increased by $150.5 million during the year.
- Capital position: Accumulated deficit was $76.9 million. Management said existing cash and investments were expected to fund planned operations for at least three years, while noting this estimate depends on assumptions and may change.
Material changes versus FY 2021
- Net loss increased by $14.4 million, while operating cash use rose by $22.5 million.
- Collaboration revenue fell by $4.2 million, largely because the prior-year period included recognition of Pediatrix’s $3.0 million upfront payment and higher revenue recognized under other collaborations.
- R&D expense declined $1.9 million, mainly on lower clinical-trial costs and stock compensation, partly offset by merger-related acquired research and development, an Aegis milestone, and regulatory consulting.
- G&A expense increased $13.8 million, reflecting higher stock compensation, marketing and consulting services, legal costs, and payroll. Merger-related replacement awards and performance-based option vesting contributed to stock compensation.
- The November merger materially changed the balance sheet and capitalization: preferred stock converted to common stock, merger proceeds strengthened liquidity, and the bank note was repaid.
Outlook, commentary, risks, and unusual items
- Regulatory outlook: FDA accepted the 2.0 mg neffy NDA for review in Q4 2022, with a mid-2023 PDUFA target action date; the EMA validated the 2.0 mg application for review in Q4 2022. Approval and timing were uncertain. The company planned a U.S. supplemental filing for the 1.0 mg dose for children weighing 15–30 kg in 2023, and reported plans for additional studies and indications.
- Development and launch spending: Management expected R&D expense could decline in 2023 as activities shift toward potential commercialization, but expected G&A expense to rise with sales, marketing, and public-company infrastructure. Both forecasts are subject to regulatory and operational uncertainty.
- Commercial assumptions: Management described a large potential market and favorable survey responses, but these are not evidence of actual demand, pricing, reimbursement, or market uptake. The product had no commercial sales and required regulatory approval.
- Territory rights: In February 2023, after year-end, ARS terminated its Recordati agreement and reacquired the related rights. It agreed to pay €3.0 million upfront, additional regulatory and commercial milestones, and sales-based payments. The change restores commercialization rights but adds payment obligations and requires ARS to secure resources or partners.
- Key risks: ARS depended on a single product candidate, had no product-sale revenue, and relied on third parties for manufacturing and supply. Other risks include regulatory review, 505(b)(2) pathway uncertainty, competition, coverage and reimbursement, intellectual-property challenges, and potential need for additional capital.
- Contingencies and unusual items: The USPTO’s February 2023 IPR decision found some claims of the ‘414 patent covering neffy patentable and other claims unpatentable; appeals or reconsideration remained possible. A securities class action against Silverback and former personnel was ongoing, with the loss range not reasonably estimable; no liability was recorded. The audit opinion on the financial statements was unqualified.
Important facts for investors to verify
- FDA and EMA review milestones, any requests for additional data, and final labeling and approval decisions for neffy.
- Cash burn, commercial-launch costs, and whether the stated liquidity runway remains consistent with updated operating plans.
- Manufacturing capacity, supplier qualification, product stability, and contingency plans for third-party supply disruptions.
- Actual payer coverage, pricing, prescription uptake, and launch economics versus management’s market research assumptions.
- Developments in the ‘414 patent proceedings, the Silverback securities litigation, and payments or obligations under the Recordati termination agreement.